Is Boston Scientific Corporation overvalued?

In our latest published analysis dated 2026-05-12, BSX looks meaningfully undervalued. The price recorded at analysis is USD 54.1 versus a composite fair-value midpoint of USD 70.4 (range USD 55.9–USD 85.1), implying roughly 30.1% upside to the midpoint at that date.

What is BSX's fair value?

Our latest published report, analyzed 2026-05-12, gives BSX a composite fair-value range of USD 55.9–USD 85.1, with a midpoint of USD 70.4. The range is triangulated across multiple valuation models and weighted by reliability for Boston Scientific Corporation's archetype; it is a dated research output, not a live price.

Should I buy BSX now?

Our latest published rating for BSX, analyzed 2026-05-12, is Strong Buy with a confidence score of 88/100. Boston Scientific Corporation looks meaningfully undervalued at the analysis-date price of USD 54.1 versus a fair-value midpoint of USD 70.4. This is research for educational purposes, not personalized investment advice.

What are the biggest risks for BSX?

The top risks our latest published report dated 2026-05-12 flags for Boston Scientific Corporation are: Multiple Compression to Peer Median; Reimbursement Rate Cuts; WATCHMAN Normalization Stall.

What is BSX's rating?

Our latest published rating for BSX, analyzed 2026-05-12, is Strong Buy, with a confidence score of 88/100 and a moat score of 9/10. It reflects the composite fair-value range (USD 55.9–USD 85.1) versus the price recorded at analysis (USD 54.1).

What archetype is BSX?

In the latest published report analyzed 2026-05-12, Boston Scientific Corporation is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for BSX.

What is BSX's free cash flow?

Free cash flow for Boston Scientific Corporation (BSX) is computed as operating cash flow minus capital expenditure. We report both the absolute level and the FCF margin against revenue, with five years of trajectory.

Operating cash flow is the primary signal: when OCF is negative or significantly below net income, the cash-flow subsection flags the divergence and traces the cause to working-capital, deferred-revenue, or earnings-quality effects.

What does BSX spend on capex?

Capital expenditure is reported as a percentage of revenue alongside the absolute number. Heavy investment phases are separated from harvesting phases so reinvestment intent is legible.

How does BSX return cash to shareholders?

The financing activity row tracks dividends paid, share repurchases, and net debt issuance. Together with FCF, it answers whether buybacks and dividends are funded organically or by issuing debt.

BSX cash flow: operating, investing, financing

Latest published researchAnalyzed 2026-05-12; report age: stale; sources: unverified. Age and source freshness are disclosed but do not remove the latest published report from discovery or indexing. Prices and valuation figures are the analysis-date snapshot, not a live quote.

Direct answer

Boston Scientific is a mature compounder in the medical device sector, benefiting from a diverse portfolio across cardiovascular, MedSurg, and rhythm management, generating strong operating cash flows and consistent margin expansion. Fair value range: low $55.9, high $85.0, with mid-point at $70.4.

CASH FLOW FAQ

BSX cash flow questions

Free cash flow for Boston Scientific Corporation (BSX) is computed as operating cash flow minus capital expenditure. We report both the absolute level and the FCF margin against revenue, with five years of trajectory.

FAQ

BSX — frequently asked questions

In our latest published analysis dated 2026-05-12, BSX looks meaningfully undervalued. The price recorded at analysis is USD 54.1 versus a composite fair-value midpoint of USD 70.4 (range USD 55.9–USD 85.1), implying roughly 30.1% upside to the midpoint at that date.

Metric	Current	Trigger threshold
Revenue growth decelerates below 6% falsification trigger.	Monitor	Deterioration versus the report thesis
Operating margins fail to sustain the 20.0% normalized assumption.	Monitor	Deterioration versus the report thesis
Peer forward P/E multiples compress, dragging the premium valuation.	Monitor

Line item	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$11.89B	$12.68B+6.6%	$14.24B+12.3%	$16.75B+17.6%	$20.07B+19.8%	+14.0%
Gross profit	$8.18B	$8.73B	$9.90B	$11.49B	$13.85B	+14.1%
Operating income	$1.82B	$2.03B	$2.42B	$3.00B	$3.97B	+21.5%
Net income	$1.04B	$698.0M-32.9%	$1.59B+127.8%	$1.85B+16.4%	$2.90B+56.8%	+29.2%
EPS (diluted)	$0.69	$0.45	$1.07	$1.25	$1.94	+29.5%
EBITDA	$2.51B	$2.75B	$3.45B	$3.86B	$5.10B	+19.4%
R&D	$1.20B	$1.32B	$1.41B	$1.62B	$2.05B	+14.3%
SG&A	$4.36B	$4.52B	$5.19B	$5.98B	$6.89B	+12.1%

BSX cash flow questions

BSX — frequently asked questions

BSX Boston Scientific Corporation fair value $56–$85

§1 Executive summary

Names readers of BSX also follow

§2 Bear case

Multiple Compression to Peer Median

Reimbursement Rate Cuts

WATCHMAN Normalization Stall

§3 Financial history

Income statement — last six periods

Quality scores

Numbers analysis

Read the full analysis — 11 more sections.